IL6 and gastric cancer: Thus, the gatekeeper role for the IL-6-dependent STAT3 signaling cascade for advanced GC is conserved between preclinical mouse models and human GC, thereby elevating ligand-specific activation of the GP130/STAT3 signaling cascade as a potential, stage-specific therapeutic target (Figure S7).